Jun 01, 2020
Sumitovant Biopharma Announces Myovant Sciences' Submission of New Drug Application (NDA) to the FDA for Once-Daily Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids
May 29, 2020
Sumitovant Biopharma Announces Myovant Sciences' Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix in Advanced Prostate Cancer and Publication in the New England Journal of Medicine
Apr 29, 2020
Sumitovant Biopharma Announces Publication of Myovant Abstracts Detailing Additional Efficacy and Safety Findings from Phase 3 Liberty Studies in Uterine Fibroids in Obstetrics & Gynecology
Apr 24, 2020
Sumitovant Biopharma Reports Key Clinical and Regulatory Milestones by Myovant Sciences
May 14, 2019
Roivant Statement on Positive Phase 3 Results from Myovant's LIBERTY 1 Study in Uterine Fibroids
Mar 19, 2019
Roivant Statement on Topline Results from EMPOWUR Phase 3 Study in Overactive Bladder
Mar 05, 2019
Myovant Sciences to Present at Upcoming Investor Conferences
Feb 07, 2019
Myovant Provides Corporate Updates and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2018
Nov 15, 2018
Myovant Sciences to Participate in Two Upcoming Investor Conferences
Oct 24, 2018
Myovant Sciences Announces Completion of Enrollment in Phase 3 HERO Trial of Relugolix in Men with Advanced Prostate Cancer
Aug 28, 2018
Myovant Sciences to Participate in Two Upcoming Investor Conferences
Aug 07, 2018
Myovant Provides Corporate Update and Reports Financial Results for First Fiscal Quarter Ended June 30, 2018
Jul 10, 2018
Roivant Sciences Provides Corporate Updates in Advance of First Annual Pipeline Day
Jul 10, 2018
Myovant Sciences Announces Completion of Screening for Phase 3 LIBERTY 1 Study Evaluating Relugolix in Women with Uterine Fibroids
Jun 07, 2018
Myovant Provides Corporate Update and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2018
Feb 13, 2018
Myovant Sciences Provides Corporate Update and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2017
Jan 04, 2018
Myovant Sciences to Present at the 36th Annual J.P. Morgan Healthcare Conference
Nov 21, 2017
Myovant Sciences to Participate in the Evercore ISI BioPharma Catalyst / Deep Dive Conference
Nov 13, 2017
Myovant Sciences Provides Corporate Update and Reports Financial Results for Second Fiscal Quarter Ended September 30, 2017
Nov 09, 2017
Myovant Sciences Announces Positive Top-line Results from Takeda's Phase 3 Study Evaluating the Efficacy and Safety of Relugolix for the Treatment of Pain Associated with Uterine Fibroids